Get the latest tech news
FDA approves first nasal spray diuretic for heart, liver and kidney disease | Aiming to prevent a common and costly issue that results in more than a million hospitalizations each year.
The US Food and Drug Administration (FDA) has approved the first intranasal diuretic for heart, liver and kidney disease patients, aiming to prevent a common and costly issue that results in more than a million hospitalizations each year.
The US Food and Drug Administration (FDA) has approved the first intranasal diuretic for heart, liver and kidney disease patients, aiming to prevent a common and costly issue that results in more than a million hospitalizations each year. In clinical studies conducted between December 2023 and April 2024, featuring 68 adults aged 18 to 55 years, the nasal spray demonstrated rapid absorption and a predictable diuretic effect comparable to IV bumetanide, including similar impacts on urine volume, sodium excretion and potassium levels. "[Bumetanide nasal spray] offers the potential to change the standard of care by enabling earlier, outpatient intervention," said Anuradha Lala-Trindade, MD, the director of heart failure research at the Mount Sinai Fuster Hospital in New York.
Or read this on r/tech
